NF1突变驱动的神经元过度兴奋设定肿瘤发生阈值并指导小鼠视神经胶质瘤治疗靶向
研究利用自发形成视路胶质瘤的Nf1突变小鼠,证实神经元midkine是Nf1-视路胶质瘤生长的必要且充分条件,拉莫三嗪可特异性抑制神经元midkine产生,阻止肿瘤进展并抑制已有肿瘤生长,且停药后效应持续数月;在两种Nf1-视路胶质瘤品系中采用儿童癫痫临床剂量拉莫三嗪可消除肿瘤生长。
要点
- 神经元midkine对Nf1-视路胶质瘤生长必要且充分。
- 拉莫三嗪特异性抑制神经元midkine产生。
- 儿童癫痫临床剂量拉莫三嗪在两种小鼠品系中消除肿瘤生长。
核心结论
- midkine和神经元过度兴奋是Nf1-视路胶质瘤生长的可靶向驱动因素。
- 支持拉莫三嗪作为NF1-视路胶质瘤儿童的潜在化学预防或化疗药物。
研究设计与样本
- 利用一组自发形成视路胶质瘤的Nf1突变小鼠,改变种系和视网膜神经元特异性midkine表达。
- 采用携带若干不同NF1患者来源种系突变的Nf1突变小鼠评估神经元兴奋性和midkine表达。
- 使用两种不同的Nf1-视路胶质瘤临床前小鼠模型评估拉莫三嗪对肿瘤进展和体内生长的影响。
主要发现
- 神经元midkine对Nf1-视路胶质瘤生长必要且充分,种系Nf1突变、神经元兴奋性、midkine产生与Nf1-视路胶质瘤增殖之间存在必然关系。
- 抗癫痫药物拉莫三嗪在抑制神经元midkine产生方面具有特异性。
- 拉莫三嗪阻止Nf1-视路胶质瘤进展,并在停药后数月内抑制已有肿瘤的生长。
- 拉莫三嗪采用儿童癫痫临床剂量在两种Nf1-视路胶质瘤品系中消除肿瘤生长。
临床怎么用
- 作者认为这些发现支持将拉莫三嗪用作NF1-视路胶质瘤儿童的潜在化学预防或化疗药物。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: With the recognition that noncancerous cells function as critical regulators of brain tumor growth, we recently demonstrated that neurons drive low-grade glioma initiation and progression. Using mouse models of neurofibromatosis type 1 (NF1)-associated optic pathway glioma (OPG), we showed that Nf1 mutation induces neuronal hyperexcitability and midkine expression, which activates an immune axis to support tumor growth, such that high-dose lamotrigine treatment reduces Nf1-OPG proliferation. Herein, we execute a series of complementary experiments to address several key knowledge gaps relevant to future clinical translation. METHODS: We leverage a collection of Nf1-mutant mice that spontaneously develop OPGs to alter both germline and retinal neuron-specific midkine expression. Nf1-mutant mice harboring several different NF1 patient-derived germline mutations were employed to evaluate neuronal excitability and midkine expression. Two distinct Nf1-OPG preclinical mouse models were used to assess lamotrigine effects on tumor progression and growth in vivo. RESULTS: We establish that neuronal midkine is both necessary and sufficient for Nf1-OPG growth, demonstrating an obligate relationship between germline Nf1 mutation, neuronal excitability, midkine production, and Nf1-OPG proliferation. We show anti-epileptic drug (lamotrigine) specificity in suppressing neuronal midkine production. Relevant to clinical translation, lamotrigine prevents Nf1-OPG progression and suppresses the growth of existing tumors for months following drug cessation. Importantly, lamotrigine abrogates tumor growth in two Nf1-OPG strains using pediatric epilepsy clinical dosing. CONCLUSIONS: Together, these findings establish midkine and neuronal hyperexcitability as targetable drivers of Nf1-OPG growth and support the use of lamotrigine as a potential chemoprevention or chemotherapy agent for children with NF1-OPG.
引用
- Anastasaki C, Chatterjee J, Koleske JP, et al. NF1 mutation-driven neuronal hyperexcitability sets a threshold for tumorigenesis and therapeutic targeting of murine optic glioma. Neuro Oncol. 2024. PMID: 38607967. doi:10.1093/neuonc/noae054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。